Sanofi Pasteur
38 Sidney Street
4th Floor
Cambridge
Massachusetts
02139
United States
Tel: 617-761-4200
Fax: 617-494-1741
Website: http://www.sanofipasteur.com/
About Sanofi Pasteur
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).41 articles about Sanofi Pasteur
-
The FDA had a busy week, approving drugs, greenlighting clinical trials and other regulatory activities for Immuneering, Amylyx, Sarepta, Sanofi, and Regeneron and more.
-
Sanofi and Regeneron presented results from the Phase III PRIME trial that showed Dupixent strongly improves itching and skin lesions in adult patients with prurigo nodularis.
-
The agreement will grant Innovent exclusive development and marketing rights to tusamitamab in China, while Sanofi will be entitled to up to $81 million in milestones and royalties.
-
As the second financial quarter of the year comes to a close, pharma and biotech companies are releasing their financial results. For more information on the top-earning companies, read on.
-
Regeneron and Sanofi's anti-inflammatory drug Dupixent has shown to be effective against five types of type 2 inflammations, with more indications expected to surface soon.
-
Under the strategic collaboration, Neurocrine Biosciences and Sosei Group Corporation will develop and commercialize novel muscarinic receptor agonists to treat the said illnesses.
-
Respiratory Syncytial Virus has been around for a very long period now. But there was no vaccine yet. But, here's the first vaccine for RSV to shape the future.
-
At the virtual Congress of the ECTRIMS meeting this week, multiple companies present data for ongoing studies of therapies for multiple sclerosis. BioSpace takes a look at some of the data.
-
Mirati and Sanofi will assess the combination of adagrasib and SAR442720 in a Phase I/II study in patients with previously treated non-small-cell lung cancer who express KRASG12C mutations.
-
ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
9/19/2021
Positive Phase 3 results for Sanofi and Regeneron Pharmaceuticals, Inc.’s Libtayo® combination treatment were presented during a late-breaking session at the European Society for Medical Oncology Virtual Congress 2021.
-
A new study on COVID-19 behavior has found that patients affected by the virus might have died due to a buildup of coronavirus directly in the lungs and not because of a secondary infection.
-
BioNTech indicates the acquisition will add production capacity in support of U.S. clinical trials.
-
LabGenius Announces Research Collaboration With Ablynx, a Sanofi Company
7/15/2021
LabGenius, a pioneer in the use of machine learning for protein engineering, announced the signing of a multi-year research collaboration with Ablynx, a Sanofi company.
-
In an interview with BioSpace, CEO Victoria Richon expressed her excitement about investor support and developing novel, first-in-class treatments.
-
Pfizer Pauses Global Sales of Smoking-Cessation Drug Chantix Over Possible Carcinogen Contamination
6/25/2021
The company indicated it was pausing distribution out of an abundance of caution and would continue investigations. -
Is an mRNA Flu Vaccine on the Horizon?
6/23/2021
The two companies will assess the safety and immunogenicity of the vaccine candidate, which codes for the hemagglutinin protein in the A/H3N2 strain of the seasonal flu virus. -
Newly licensed US manufacturing facility to increase availability of Fluzone® High-Dose Quadrivalent (influenza vaccine)
6/17/2021
The U.S. Food and Drug Administration Center for Biologics Evaluation and Research has granted approval to Sanofi Pasteur, the vaccines global business unit of Sanofi, for an additional influenza manufacturing facility located in Swiftwater, PA.
-
Translate Bio Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine Program
6/7/2021
-- $50 million milestone payment to be received this month for successful manufacturing, release, and delivery of clinical drug product to support influenza mRNA vaccine clinical trial anticipated to begin in the coming weeks --
-
Sanofi and Merck's first and only six-in-one pediatric combination vaccine now available in the United States
6/1/2021
This combination vaccine may simplify execution and reduce shots needed to complete CDC's recommended child and adolescent immunization schedule
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.